Welcome to our dedicated page for Angle Plc news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on Angle Plc stock.
Overview of Angle Plc
Angle Plc (ANPCY) is a world-class liquid biopsy company that specializes in the innovative capture and analysis of circulating tumour cells (CTCs) from a simple blood sample. Emphasizing technical precision and validated methodologies, the company has established itself in the fields of clinical oncology, research, and pharmaceutical drug development. Using its patent-protected Parsortix system and complementary diagnostic assays, Angle Plc addresses a critical need in cancer diagnostics by enabling comprehensive downstream analysis—including whole cell imaging, proteomic, genomic, and transcriptomic analyses.
Core Technologies and Business Model
At the heart of Angle Plc's operations is the Parsortix system, an innovative cell harvesting technology designed to capture intact CTCs based on their size and deformability. This method overcomes the limitations of traditional EpCAM-based enrichment techniques by preserving the morphology and viability of harvested cells. The company has further enhanced its technology portfolio with developments such as the proprietary CellKeep slide, which significantly reduces cell loss during microscopy preparation, and specialized assays including DNA Damage Response (DDR) and Androgen Receptor detection assays.
Clinical and Research Applications
Angle Plc's technology is integral to both clinical diagnostics and research-oriented environments. Its robust system facilitates the identification and characterization of rare CTCs, thereby supporting:
- Drug Development: Custom assay development and clinical trial testing enhance the precision of targeted therapies.
- Clinical Oncology: Advanced CTC profiling offers longitudinal, minimally invasive monitoring of molecular markers tied to cancer progression and treatment response.
- Pharma Services: Strategic partnerships with major pharmaceutical companies underscore the application of the Parsortix system in assessing novel cancer therapeutics, thereby enabling more efficient patient stratification.
Market Position and Competitive Landscape
Angle Plc occupies a distinctive niche within the liquid biopsy market by combining multifunctional technologies with comprehensive clinical service offerings. While there are competitors in the broader liquid biopsy and diagnostic space, Angle Plc differentiates itself through its focus on harvesting complete, intact cells rather than fragmented DNA alone. This capability underpins their growing portfolio of peer-reviewed publications and strategic collaborations that collectively enhance the company's credibility and position in the competitive landscape.
Expertise and Technological Advancements
Deep industry expertise is evident in Angle Plc's continuous innovation in assay development and technology refinement. The company has achieved several milestones, including securing intellectual property rights in major jurisdictions and demonstrating superior performance in multiple, independent clinical studies. Its pioneering work in combining CTC analysis with next generation sequencing (NGS) further reinforces its status as a key player in the advancement of liquid biopsy technology for precision oncology.
Operational Excellence
Angle Plc operates a dual business model with a focus on both diagnostic products and custom clinical services. The diagnostic product suite emphasizes high-sensitivity, patented systems and consumables, while its clinical services include assay development and standardized testing in GCP/GCLP compliant laboratories. This integrated approach allows the company to offer comprehensive solutions to research institutions, drug developers, and clinical trial sponsors globally.
Significance in the Oncological Landscape
By enabling the detailed analysis of CTCs, Angle Plc significantly contributes to the paradigm shift towards personalized and precision medicine in oncology. Its methodologies not only increase assay sensitivity but also provide a deeper understanding of cancer biology, ultimately helping to bridge the gap between laboratory research and clinical application. The company’s commitment to extracting high-quality, actionable insights from liquid biopsy samples sets it apart as an innovator in the diagnostic field.
In Summary
Angle Plc is a testament to the evolving nature of cancer diagnostics and research. With its expertise in liquid biopsy technology, particularly in the innovative capture and analysis of circulating tumour cells, the company is well-equipped to support clinical oncology, pharmaceutical research, and drug development. Its comprehensive and continually refined portfolio of diagnostic tools and clinical services provides invaluable insights for advancing personalized cancer therapy.
ANGLE plc has announced a pivotal study revealing significant differences in EGFR mutations between circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients. Conducted by a research team from the University of Athens, this study highlights the importance of analyzing CTCs for better treatment decisions. The results indicate CTCs can provide real-time insights into tumor evolution and resistance, unlike ctDNA, which offers historical data. This research underscores the potential of liquid biopsies in safer, cost-effective monitoring of cancer progression.
ANGLE plc (OTCQX:ANPCY) has confirmed the completion of its response to the FDA's Additional Information Request regarding the Parsortix system, a liquid biopsy technology. The comprehensive response has been submitted as planned, and the company expects a regulatory decision during H2 2021. The Parsortix system aims to become the first FDA-cleared device for harvesting circulating tumor cells (CTCs), enhancing cancer diagnostics. The De Novo process entails inherent uncertainties regarding timing and success, yet ANGLE remains optimistic about the FDA's review outcome.
ANGLE plc announces promising research from Washington University School of Medicine demonstrating the effectiveness of the Parsortix system in isolating rare cancer cells from breast cancer patients' bone marrow. This breakthrough could enhance the identification of biomarkers, leading to targeted treatments that may prevent relapse in patients in remission. With breast cancer affecting 3.7 million women in the US, the research indicates Parsortix's potential to eradicate dormant Disseminated Tumor Cells (DTCs) and improve patient outcomes.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) announced the issuance of 216,000 new Ordinary shares following the exercise of employee options. These shares will rank equally with existing shares. An application for their trading admission on AIM has been submitted, with trading anticipated to begin on 24 May 2021. Post-admission, the total number of Ordinary Shares will stand at 215,867,845. The company continues to develop its liquid biopsy technology, particularly the Parsortix system, which has shown promise in clinical studies for cancer diagnostics.
ANGLE plc (OTCQX:ANPCY) announced significant advancements from a study conducted by the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy, focusing on triple negative breast cancer (TNBC). The study utilized ANGLE's Parsortix system to isolate circulating tumor cells (CTCs) concurrently with circulating tumor DNA (ctDNA) from a single blood sample. This method revealed multiple druggable targets associated with 12 FDA-approved treatment options. This research highlights the potential for non-invasive monitoring and precision therapy in TNBC, which is known for its limited treatment options and aggressive nature.
ANGLE plc (AIM: AGL OTCQX: ANPCY) has issued 203,333 new Ordinary shares following the exercise of employee options. The shares, valued at £0.10 each, will rank pari passu with existing shares. Admission to trading on AIM is expected to commence on 7 May 2021, increasing the total number of Ordinary Shares to 215,651,845. The company is known for its liquid biopsy technology, particularly its Parsortix system, which aims to transform cancer diagnostics and monitoring.
ANGLE plc has reported its preliminary results for the year ending December 31, 2020, highlighting significant operational and financial developments. The company made a full De Novo FDA submission for the Parsortix system aimed at capturing circulating tumor cells. Key achievements include the completion of patient enrollment for an ovarian cancer study and the signing of a large-scale contract with a pharmaceutical customer, potentially generating up to US$1.2 million in revenue. Financially, revenue increased to £0.8 million, while losses rose to £11.6 million.
ANGLE plc has completed patient enrolment in a 200-patient ovarian cancer clinical verification study at the University of Rochester. The study evaluates the effectiveness of ANGLE's Parsortix system and HyCEAD platform for detecting ovarian cancer through a simple blood test. The study aims to finalize data by Q2 2021 and report results in Q4 2021. If successful, ANGLE plans to launch the test as a laboratory-developed test (LDT) by year-end, potentially addressing a market worth up to $1.8 billion in the U.S. alone.
ANGLE has announced a significant contract potentially worth US$1.2 million over 18 months with a major pharmaceutical company to utilize its Parsortix system.
This contract marks the first large-scale application of Parsortix in cancer drug trials, focusing on prostate cancer and other solid tumors. The system, which captures circulating tumor cells (CTCs) for analysis, enables ongoing monitoring of patients during clinical trials, surpassing traditional tissue biopsies in providing vital insights into cancer treatment.
FAQ
What is the current stock price of Angle Plc (ANPCY)?
What is the market cap of Angle Plc (ANPCY)?
What is Angle Plc's primary area of expertise?
How does the Parsortix system work?
What are the main products and services offered by Angle Plc?
How does Angle Plc differentiate itself from competitors?
What role do innovations like the CellKeep slide play in their technology?
How are Angle Plc’s technologies applied in the clinical setting?
What significance do Angle Plc’s partnerships hold?
